1. Home
  2. GAUZ vs CLLS Comparison

GAUZ vs CLLS Comparison

Compare GAUZ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAUZ
  • CLLS
  • Stock Information
  • Founded
  • GAUZ 2009
  • CLLS 1999
  • Country
  • GAUZ Israel
  • CLLS France
  • Employees
  • GAUZ 636
  • CLLS N/A
  • Industry
  • GAUZ Industrial Machinery/Components
  • CLLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GAUZ Miscellaneous
  • CLLS Health Care
  • Exchange
  • GAUZ Nasdaq
  • CLLS Nasdaq
  • Market Cap
  • GAUZ 159.1M
  • CLLS 148.1M
  • IPO Year
  • GAUZ 2024
  • CLLS 2007
  • Fundamental
  • Price
  • GAUZ $8.81
  • CLLS $1.45
  • Analyst Decision
  • GAUZ Strong Buy
  • CLLS Buy
  • Analyst Count
  • GAUZ 4
  • CLLS 3
  • Target Price
  • GAUZ $16.25
  • CLLS $7.00
  • AVG Volume (30 Days)
  • GAUZ 48.8K
  • CLLS 120.5K
  • Earning Date
  • GAUZ 05-10-2025
  • CLLS 05-27-2025
  • Dividend Yield
  • GAUZ N/A
  • CLLS N/A
  • EPS Growth
  • GAUZ N/A
  • CLLS N/A
  • EPS
  • GAUZ N/A
  • CLLS N/A
  • Revenue
  • GAUZ $103,527,000.00
  • CLLS $49,217,000.00
  • Revenue This Year
  • GAUZ $32.83
  • CLLS $1.26
  • Revenue Next Year
  • GAUZ $42.86
  • CLLS N/A
  • P/E Ratio
  • GAUZ N/A
  • CLLS N/A
  • Revenue Growth
  • GAUZ 32.76
  • CLLS 435.38
  • 52 Week Low
  • GAUZ $6.78
  • CLLS $1.10
  • 52 Week High
  • GAUZ $17.10
  • CLLS $3.38
  • Technical
  • Relative Strength Index (RSI)
  • GAUZ N/A
  • CLLS 60.38
  • Support Level
  • GAUZ N/A
  • CLLS $1.40
  • Resistance Level
  • GAUZ N/A
  • CLLS $1.56
  • Average True Range (ATR)
  • GAUZ 0.00
  • CLLS 0.09
  • MACD
  • GAUZ 0.00
  • CLLS 0.03
  • Stochastic Oscillator
  • GAUZ 0.00
  • CLLS 76.09

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Share on Social Networks: